Skip to main content

Advertisement

SpringerLink
Log in

The use of etanercept in a patient with disseminated tuberculosis

  • Case Report
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Tumor necrosis factor (TNF) is a central regulator of chronic inflammatory diseases and plays a major role in the host immune system against tuberculosis (TB). TNF antagonists, infliximab and etanercept are effective in treating chronic inflammatory diseases by inhibiting TNF, but increase the risk of TB as a result of immunosuppression. Previous studies have shown that the risk of TB is greater in patients who received infliximab than in those who received etanercept and several hypotheses on the action mechanisms of the two agents have been presented in order to explain this difference in the risk of TB. As the clinical use of TNF antagonists increase, the incidence rate of TB may increase. Therefore, it is necessary that clinicians considering the use of TNF antagonists pay much attention to the prevention and control of TB and understand the mechanisms of action of the TNF antagonists. This case shows that etanercept treatment can be safely administered during the treatment of TB. In the future, additional studies will be needed to determine the safety of etanercept and the optimal time for the administration of etanercept during the TB treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Haraoui B (2005) The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 72:46–47

    PubMed  Google Scholar 

  2. Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J (2003) Biologic therapies in the spondyloarthritis: new opportunities, new challenges. Curr Opin Rheumatol 15:394–407. doi:10.1097/00002281-200307000-00005

    Article  PubMed  CAS  Google Scholar 

  3. Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D et al (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28. doi:10.1016/S0016-5085(99)70224-6

    Article  PubMed  CAS  Google Scholar 

  4. Ehlers S (2003) Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 62(Suppl 2):ii37–ii42. doi:10.1136/ard.62.suppl_2.ii37

    PubMed  CAS  Google Scholar 

  5. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265. doi:10.1086/383317

    Article  PubMed  CAS  Google Scholar 

  6. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN et al (2002) Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor antagonists infliximab and etanercept. Arthritis Rheum 46:2565–2570. doi:10.1002/art.10583

    Article  PubMed  CAS  Google Scholar 

  7. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418–426. doi:10.1124/jpet.301.2.418

    Article  PubMed  CAS  Google Scholar 

  8. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, Chan J et al (2007) Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195:1643–1650. doi:10.1086/517519

    Article  PubMed  CAS  Google Scholar 

  9. Ehlers S (2005) Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 41:S199–S203. doi:10.1086/429998

    Article  PubMed  CAS  Google Scholar 

  10. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7:251–259. doi:10.1006/cyto.1995.0029

    Article  PubMed  CAS  Google Scholar 

  11. Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B et al (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793–802. doi:10.1016/0092-8674(95)90192-2

    Article  PubMed  CAS  Google Scholar 

  12. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194:486–492. doi:10.1086/505430

    Article  PubMed  CAS  Google Scholar 

  13. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M et al (2004) A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18:257–264. doi:10.1097/00002030-200401230-00015

    Article  PubMed  CAS  Google Scholar 

  14. Manadan AM, Joyce K, Sequeira W, Block JA (2007) Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol 25:743–745

    PubMed  CAS  Google Scholar 

  15. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148–155. doi:10.1016/S1473-3099(03)00545-0 (review)

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, South Korea

    Ji-Yun Kim, Ji-Na Park, Jae Gun Lee, Yeon-Ah Lee, Yee-Hyung Kim, Seung-Jae Hong, Hyung-In Yang & Sang-Hoon Lee

Authors
  1. Ji-Yun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ji-Na Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jae Gun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yeon-Ah Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yee-Hyung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seung-Jae Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hyung-In Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sang-Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sang-Hoon Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, JY., Park, JN., Lee, J.G. et al. The use of etanercept in a patient with disseminated tuberculosis. Rheumatol Int 29, 1377–1380 (2009). https://doi.org/10.1007/s00296-008-0836-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-008-0836-9

Keywords

Search

Navigation